| Multiple Sclerosis, Relapsing-Remitting
Ponvory vs Tecfidera
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Ponvory vs Tecfidera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecfidera has a higher rate of injection site reactions vs Ponvory based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecfidera but not Ponvory, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ponvory
Tecfidera
At A Glance
Oral
Once daily
S1P receptor 1 modulator
Oral
Twice daily
Nrf2 pathway activator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis Initiate with 14-day oral dose titration starting at 2 mg once daily per schedule; maintenance dose is 20 mg orally once daily beginning Day 15.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive Starting dose 120 mg twice a day orally for 7 days; maintenance dose 240 mg twice a day orally.
Contraindications
- Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Known hypersensitivity to dimethyl fumarate or any excipient of TECFIDERA
Adverse Reactions
Most common (>=10%) Upper respiratory tract infection, hepatic transaminase elevation, hypertension
Serious Infections, bradyarrhythmia and AV conduction delays, respiratory effects, liver injury, increased blood pressure, cutaneous malignancies, macular edema, posterior reversible encephalopathy syndrome, severe increase in disability after stopping
Most common (>=10%) Flushing, abdominal pain, diarrhea, nausea
Serious Anaphylaxis, angioedema, progressive multifocal leukoencephalopathy, herpes zoster and other serious opportunistic infections, lymphopenia, liver injury
Postmarketing Acute pancreatitis, gastrointestinal perforation, ulceration, obstruction, and hemorrhage, liver function abnormalities, herpes zoster infection, rhinorrhea, alopecia
Pharmacology
Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1 and blocks lymphocyte egress from lymph nodes, reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.
Dimethyl fumarate (DMF) and its active metabolite monomethyl fumarate (MMF) activate the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway involved in the cellular response to oxidative stress; the mechanism by which DMF exerts its therapeutic effect in multiple sclerosis is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ponvory
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
Tecfidera
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ponvory
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Tecfidera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Ponvory
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Tecfidera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PonvoryView full Ponvory profile
TecfideraView full Tecfidera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.